Mars, Incorporated has acquired Cerba Vet and ANTAGENE to enhance its veterinary diagnostics portfolio in France, addressing the growing need for advanced solutions in pet healthcare.

Information on the Target

Cerba Vet and ANTAGENE, renowned entities in the veterinary diagnostics field, have recently been acquired by Mars, Incorporated. This acquisition marks a significant enhancement to Mars's existing portfolio, allowing for a more comprehensive suite of diagnostic solutions tailored for veterinary professionals. Cerba Vet specializes in providing laboratory diagnostics services, while ANTAGENE is known for its genetic testing capabilities, both of which play a critical role in supporting the health and well-being of pets.

By integrating Cerba Vet and ANTAGENE into its operations, Mars aims to elevate the standards of veterinary care through innovative diagnostic technology and improved accessibility to essential services for veterinarians and pet owners alike. This strategic move aligns with Mars Petcare's commitment to advancing pet healthcare and enriches its Science & Diagnostics division.

Industry Overview in France

The veterinary diagnostics industry in France has seen dynamic growth due to an increasing demand for advanced medical services for pets. Pet ownership rates are on the rise, and as a result, there is a heightened focus on pet health,